Literature DB >> 32333332

Acromegaly and joint pain: is there something more? A cross-sectional study to evaluate rheumatic disorders in growth hormone secreting tumor patients.

N Prencipe1, M Scarati2, T Manetta3, A M Berton4, S Parisi5, C Bona4, M Parasiliti-Caprino4, M C Ditto5, V Gasco4, E Fusaro5, S Grottoli4.   

Abstract

PURPOSE: The aim of the present study was to evaluate the rheumatic profile in acromegalic patients to better characterize joint pain.
METHODS: The immunological pattern (rheumatoid factor; antinuclear antibodies-ANA, extractable nuclear antigens-ENA-Ab; anti-citrullinated protein antibodies; erythrocyte sedimentation rate) was evaluated in 20 acromegaly subjects (AS) and 20 control subjects (CS). Bilateral joint ultrasound of hands/wrists and nail capillaroscopy were also performed.
RESULTS: Articular pain was more frequent in AS than in CS (p = 0.027). No difference was detected in immunological parameters. ANA and ENA-Ab were positive in only 10% of AS and in 5% of CS, while no difference was found in anti-citrullinated protein antibodies. No difference was detected between rheumatoid factor positivity, but threefold higher IgG were detected in AS compared to CS. The erythrocyte sedimentation rate was significantly higher in AS than CS (p = 0.040), while in AS, there was a trend in increased Power Doppler (PWD) articular uptake. The capillaroscopic evaluation showed a significant difference in almost each parameter (presence and number of tortuous capillaries, capillary enlargements, and hemorrhages), showing a moderate-to-severe microangiopathy in AS.
CONCLUSION: The results of our study suggest that joint damage in acromegaly has not an autoimmune etiology. Increased erythrocyte sedimentation rate levels and PWD alteration in acromegalic population reflect a possible inflammatory nature, while the capillaroscopic findings suggest a moderate-to-severe microangiopathy that could help to identify patients with a greater macroangiopathic risk.

Entities:  

Keywords:  IGF-I; Joint; Microvascular; Pituitary; Rheumatic factor

Mesh:

Substances:

Year:  2020        PMID: 32333332     DOI: 10.1007/s40618-020-01268-8

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  2 in total

1.  Clinical and functional outcome of total hip arthroplasty in patients with acromegaly: mean twelve year follow-up.

Authors:  Mustafa Akkaya; Antonio Pignataro; Nemandra Sandiford; Thorsten Gehrke; Mustafa Citak
Journal:  Int Orthop       Date:  2022-05-21       Impact factor: 3.479

2.  Co-Occurrence of ANCA-Associated Vasculitis and Sjögren's Syndrome in a Patient With Acromegaly: A Case Report and Retrospective Single-Center Review of Acromegaly Patients.

Authors:  Philipp S Fuchs; Jonas Lötscher; Caroline M Berkemeier; Julia R Hirsiger; Adhideb Ghosh; Quan-Zhen Li; Nikolaus Deigendesch; Emanuel Christ; Alexander A Navarini; Mike Recher; Thomas Daikeler; Ingmar A F M Heijnen; Christoph T Berger
Journal:  Front Immunol       Date:  2020-12-21       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.